Sutro Biopharma 과거 순이익 실적

과거 기준 점검 0/6

Sutro Biopharma 의 수입은 연평균 -26.9%의 비율로 감소해 온 반면, Biotechs 산업은 연평균 22.8%의 비율로 증가했습니다. 매출은 연평균 19.2%의 비율로 증가해 왔습니다.

핵심 정보

-26.88%

순이익 성장률

-12.61%

주당순이익(EPS) 성장률

Biotechs 산업 성장률	17.04%
매출 성장률	19.15%
자기자본이익률	n/a
순이익률	-205.18%
최근 순이익 업데이트	30 Sep 2025

최근 과거 실적 업데이트

Recent updates

Here's Why We're A Bit Worried About Sutro Biopharma's (NASDAQ:STRO) Cash Burn Situation

Jul 01

Benign Growth For Sutro Biopharma, Inc. (NASDAQ:STRO) Underpins Stock's 36% Plummet

Apr 18

ADC Pipeline Focus Will Advance Preclinical Drug Development

Apr 03 Strategic focus on preclinical programs and restructuring is set to drive future growth by enhancing drug development and revenue potential.

Sutro Biopharma, Inc. (NASDAQ:STRO) Not Doing Enough For Some Investors As Its Shares Slump 25%

Mar 04

Sutro Biopharma: I Don't Buy That Their Pipeline Is Worthless

Jan 02

Why Investors Shouldn't Be Surprised By Sutro Biopharma, Inc.'s (NASDAQ:STRO) 26% Share Price Plunge

Nov 30

Revenues Working Against Sutro Biopharma, Inc.'s (NASDAQ:STRO) Share Price Following 25% Dive

Oct 11

Sutro Biopharma's Competitive ADCs Position It For Future Growth In Oncology

Sep 23

There's No Escaping Sutro Biopharma, Inc.'s (NASDAQ:STRO) Muted Revenues Despite A 29% Share Price Rise

Aug 24

Brokers Are Upgrading Their Views On Sutro Biopharma, Inc. (NASDAQ:STRO) With These New Forecasts

Aug 22

Analysts Are Upgrading Sutro Biopharma, Inc. (NASDAQ:STRO) After Its Latest Results

Aug 16

The Market Doesn't Like What It Sees From Sutro Biopharma, Inc.'s (NASDAQ:STRO) Revenues Yet As Shares Tumble 28%

Jun 26

We Think The Compensation For Sutro Biopharma, Inc.'s (NASDAQ:STRO) CEO Looks About Right

May 31

Bearish: Analysts Just Cut Their Sutro Biopharma, Inc. (NASDAQ:STRO) Revenue and EPS estimates

Apr 02

The Market Doesn't Like What It Sees From Sutro Biopharma, Inc.'s (NASDAQ:STRO) Revenues Yet

Mar 28

Sutro Biopharma, Inc.'s (NASDAQ:STRO) Price Is Right But Growth Is Lacking After Shares Rocket 43%

Dec 19

Is Sutro Biopharma (NASDAQ:STRO) Using Debt In A Risky Way?

Aug 24

Is Sutro Biopharma (NASDAQ:STRO) Using Too Much Debt?

Feb 10

An Intrinsic Calculation For Sutro Biopharma, Inc. (NASDAQ:STRO) Suggests It's 47% Undervalued

Jan 12

Sutro Biopharma: Partnership Progress Warrants Exposure

Aug 16

New Forecasts: Here's What Analysts Think The Future Holds For Sutro Biopharma, Inc. (NASDAQ:STRO)

Aug 11

Sutro Biopharma GAAP EPS of -$0.55, revenue of $28.1M

Aug 08

Sutro to get $10M payment from Merck after first patient dosed in collaboration trial

Jul 26

Is Sutro Biopharma (NASDAQ:STRO) Using Too Much Debt?

May 02

매출 및 비용 세부 내역

Sutro Biopharma가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.

순이익 및 매출 추이

NasdaqGM:STRO 매출, 비용 및 순이익 (USD Millions)
날짜	매출	순이익	일반관리비	연구개발비
30 Sep 25	106	-217	41	240
30 Jun 25	104	-209	47	240
31 Mar 25	66	-245	49	235
31 Dec 24	62	-227	48	240
30 Sep 24	161	-124	56	169
30 Jun 24	169	-124	57	169
31 Mar 24	154	-115	60	222
31 Dec 23	154	-107	63	169
30 Sep 23	49	-172	60	0
30 Jun 23	57	-143	60	0
31 Mar 23	75	-130	60	0
31 Dec 22	68	-119	60	127
30 Sep 22	70	-123	61	0
30 Jun 22	53	-134	63	0
31 Mar 22	53	-114	60	0
31 Dec 21	62	-106	56	0
30 Sep 21	60	-127	48	0
30 Jun 21	69	-79	41	0
31 Mar 21	50	-43	39	0
31 Dec 20	43	-32	37	0
30 Sep 20	46	13	38	0
30 Jun 20	40	-17	36	0
31 Mar 20	41	-61	34	0
31 Dec 19	43	-56	33	0
30 Sep 19	51	-42	32	0
30 Jun 19	46	-40	29	0
31 Mar 19	41	-38	25	0
31 Dec 18	38	-35	22	0
30 Sep 18	23	-49	18	0
30 Jun 18	33	-40	18	0
31 Mar 18	42	-30	17	0
31 Dec 17	52	-20	16	0
31 Dec 16	60	0	15	0

양질의 수익: STRO 은(는) 현재 수익성이 없습니다.

이익 마진 증가: STRO는 현재 수익성이 없습니다.

잉여현금흐름 대비 순이익 분석

과거 순이익 성장 분석

수익추이: STRO은 수익성이 없으며 지난 5년 동안 손실이 연평균 26.9% 증가했습니다.

성장 가속화: 현재 수익성이 없어 지난 1년간 STRO의 수익 성장률을 5년 평균과 비교할 수 없습니다.

수익 대 산업: STRO은 수익성이 없어 지난 해 수익 성장률을 Biotechs 업계(52.4%)와 비교하기 어렵습니다.

자기자본이익률

높은 ROE: STRO의 부채가 자산을 초과하여 자본 수익률을 계산하기 어렵습니다.

총자산이익률

투하자본수익률

우수한 과거 실적 기업을 찾아보세요

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2025/11/19 09:17
종가	2025/11/18 00:00
수익	2025/09/30
연간 수익	2024/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 Github 페이지에서 확인할 수 있으며, 보고서 활용 방법에 대한 가이드와 Youtube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Sutro Biopharma, Inc.는 16명의 분석가가 다루고 있습니다. 이 중 10명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Zhiqiang Shu	Berenberg
Tazeen Ahmad	BofA Global Research
Thomas Shrader	BTIG

Sutro Biopharma 과거 순이익 실적

과거 기준 점검 0/6

핵심 정보

최근 과거 실적 업데이트

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2022 earnings: EPS exceeds analyst expectations

Recent updates

Sutro Biopharma, Inc. Highlights Next-Generation ADC Innovation at Virtual R&D Day

Sutro Biopharma Announces Operational Restructuring Intended to Extend Cash Runway Through Key Milestones

Here's Why We're A Bit Worried About Sutro Biopharma's (NASDAQ:STRO) Cash Burn Situation

Sutro Biopharma, Inc.(NasdaqGM:STRO) dropped from Russell 2000 Dynamic Index

Sutro Biopharma Receives Written Notice from the Nasdaq Stock Market

Sutro Biopharma, Inc Appoints Greg Chow as Chief Financial Officer, Effective June 2, 2025

Benign Growth For Sutro Biopharma, Inc. (NASDAQ:STRO) Underpins Stock's 36% Plummet

Sutro Biopharma, Inc., Annual General Meeting, Jun 06, 2025

John Freund Decides Not to Stand for Re-Election At the AGM of Sutro Biopharma, Inc

ADC Pipeline Focus Will Advance Preclinical Drug Development

Sutro Biopharma, Inc. Presents Data from Dose-Optimization Portion of Reframe-O1 Trial in Patients with Platinum Resistant Ovarian Cancer At SGO 2025

Sutro Biopharma Announces CEO Changes

Sutro Biopharma, Inc. (NASDAQ:STRO) Not Doing Enough For Some Investors As Its Shares Slump 25%

Sutro Biopharma: I Don't Buy That Their Pipeline Is Worthless

Sutro Biopharma Announces Selected Dose for Luvelta and Topline Results from Dose-Optimization Portion of Reframe-O1 Trial in Platinum Resistant Ovarian Cancer

Why Investors Shouldn't Be Surprised By Sutro Biopharma, Inc.'s (NASDAQ:STRO) 26% Share Price Plunge

Sutro Biopharma, Inc. Announces Initiation of the Registration-Enabling REFRaME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML

Revenues Working Against Sutro Biopharma, Inc.'s (NASDAQ:STRO) Share Price Following 25% Dive

Sutro Biopharma Highlights Next-Generation ADC Innovation and Near-Term Pipeline At Research Forum

Sutro Biopharma's Competitive ADCs Position It For Future Growth In Oncology

Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO2024

There's No Escaping Sutro Biopharma, Inc.'s (NASDAQ:STRO) Muted Revenues Despite A 29% Share Price Rise

Brokers Are Upgrading Their Views On Sutro Biopharma, Inc. (NASDAQ:STRO) With These New Forecasts

Sutro Biopharma Announces Initiation of REFRaME-L1 Phase 2 Trial with Luvelta for Patients with Non-Small Cell Lung Cancer

Analysts Are Upgrading Sutro Biopharma, Inc. (NASDAQ:STRO) After Its Latest Results

Sutro Biopharma Appoints Dr. Barbara Leyman as Chief Business Development Officer

The Market Doesn't Like What It Sees From Sutro Biopharma, Inc.'s (NASDAQ:STRO) Revenues Yet As Shares Tumble 28%

We Think The Compensation For Sutro Biopharma, Inc.'s (NASDAQ:STRO) CEO Looks About Right

Consensus revenue estimates fall by 16%

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased by 7.1% to US$12.80

Sutro Biopharma, Inc. Announces Initiation of Randomized Portion (Part 2) of REFRaME-O1 Trial

Sutro Biopharma, Inc., Annual General Meeting, Jun 06, 2024

Price target decreased by 12% to US$12.89

Sutro Biopharma, Inc. has completed a Follow-on Equity Offering in the amount of $74.999998 million.

Bearish: Analysts Just Cut Their Sutro Biopharma, Inc. (NASDAQ:STRO) Revenue and EPS estimates

Sutro Biopharma, Inc. has filed a Follow-on Equity Offering in the amount of $74.999998 million.

Consensus revenue estimates fall by 28%

The Market Doesn't Like What It Sees From Sutro Biopharma, Inc.'s (NASDAQ:STRO) Revenues Yet

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Chief Medical Officer exercised options and sold US$64k worth of stock

Insider notifies of intention to sell stock

Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolRa-Targeting ADC

Sutro Biopharma, Inc.'s (NASDAQ:STRO) Price Is Right But Growth Is Lacking After Shares Rocket 43%

Price target decreased by 13% to US$14.67

Sutro Biopharma, Inc. Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin (luvelta) in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023

Sutro Biopharma, Inc Appoints Jane Chung as President and Chief Operating Officer

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Share price stability

Sutro Biopharma Announces Presentation of Data for Luveltamab Tazevibulin (luvelta) from the Phase 1 Dose-Expansion Study in Endometrial Cancers At ESMO 2023

Price target decreased by 9.9% to US$16.89

Sutro Biopharma, Inc. Appoints Hans Peter Gerber as Chief Scientific Officer

Chief Business Officer recently sold US$53k worth of stock

Chief Business Officer notifies of intention to sell stock

Is Sutro Biopharma (NASDAQ:STRO) Using Debt In A Risky Way?

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus revenue estimates increase by 10%

Price target decreased by 8.6% to US$17.71

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased by 7.1% to US$19.75

Full year 2022 earnings: EPS exceeds analyst expectations

CEO & Director exercised options and sold US$100k worth of stock

CFO & Secretary exercised options to buy US$284k worth of stock.

Is Sutro Biopharma (NASDAQ:STRO) Using Too Much Debt?

An Intrinsic Calculation For Sutro Biopharma, Inc. (NASDAQ:STRO) Suggests It's 47% Undervalued

Sutro Biopharma, Inc. Announces Results from Phase 1 Dose-Expansion Study of STRO-002

Consensus revenue estimates fall by 18%

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$24.63